Clinical trials: Polymyalgia Rheumatica (PMR)
Polymyalgia Rheumatica
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult…
- Trial name
- REPLENISH (NCT05767034)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 132 sites in United States, Argentina and 24 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Polymyalgia Rheumatica
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older.
- Trial name
- AIM-PMR (NCT04972968)
- Testing
- ABBV-154, Glucocorticoid
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 181 people
- Sponsor
- AbbVie
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
- Trial name
- NCT06281236
- Testing
- Prednisolone, SPI-62
- Where
- 5 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Sparrow Pharmaceuticals
Polymyalgia Rheumatica
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.
- Trial name
- NCT01821040
- Testing
- Lodotra®, Prednisone IR (immediate release)
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Mundipharma Research Limited
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)
This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.
- Trial name
- NCT05436652
- Testing
- SPI-62, Prednisolone 10mg, Additional prednisolone
- Where
- 10 sites in Germany, Poland
- Volunteers
- 66 people
- Sponsor
- Sparrow Pharmaceuticals
Polymyalgia Rheumatica
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Trial name
- REPLENISH-EXT (NCT06331312)
- Testing
- Secukinumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals